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Available online 11 April 2012Abstract Background: The early- to mid-term impact of bone-marrow-derived stem cells (BMC) on diastolic function and
exercise capacity after acute myocardial infarction (AMI) remains controversial. We performed a systematic analysis to assess
whether BMC transfer is related to an early improvement in diastolic function and exercise capacity after AMI.
Methods: Randomized controlled trials (RCTs) of BMC therapy after AMI were extracted from MEDLINE, EMBASE and CENTRAL
and analyzed for a change in tissue Doppler annular early (Ea) and late diastolic (Aa) velocities, mitral inflow E velocity to
tissue Doppler Ea (E/Ea) ratio, exercise time and exercise capacity.
Results: A total of 365 patients were included from 6 trials. A greater improvement was observed in the E/Ea ratio after 1 year
in the BMC group compared to the control group. Additionally, the BMC-treated patients had a larger improvement in exercise
time, ventilation/CO2 production (VE/VCO2 slope) and respiratory exchange ratio (RER) after 1 year.
Conclusion: The results indicate that intracoronary BMC treatment in AMI patients leads to a mid-term improvement in diastolic
function and exercise capacity.
© 2012 Elsevier B.V. All rights reserved.Abbreviations: RCT, Randomized controlled trial; E/A ratio, transmitral early peak (E)/late peak (A) velocities; mitral E/Ea, inflow E
velocity to tissue Doppler Ea ratio; IVRT, isovolumic relaxation time; DT, E-wave deceleration time; PVR, pulmonary vascular resistance; VO2,
oxygen consumption; VE/VCO2 slope, ventilation/CO2 production; RER, respiratory exchange ratio; AMI, acute myocardial infarction; G-CSF,
granulocyte colony-stimulating factor; BMC, bone marrow-derived cells; IC, intracoronary therapy; CABG, coronary artery bypass graft; LVEF,
left ventricular ejection fraction; PCI, percutaneous coronary intervention; WMD, weighted mean difference; CI, confidence interval; HF,
heart failure; LV, left ventricular
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In the last decade, stem cell therapy has been introduced as a
novel treatment for acute myocardial infarction (AMI)
(Bouchentouf et al., 2010; Silva et al., 2009). Although the
benefits to overall systolic function have been confirmed, the
effect of stem cells on diastolic function has been rarely
studied. Experimental studies have suggested that the
myocardial transfer of bone-marrow-derived cells (BMCs)
may enhance diastolic function after MI (Limbourg and
Drexler, 2005; Orlic et al., 2001), but the early- and mid-
term clinical effects of intracoronary BMCs have been con-
tradictory. The BOOST trial (Schaefer et al., 2006) concluded
that BMC transfer improved diastolic function at 6-month
follow up, whereas Herbots et al. (Herbots et al., 2009) did not
find a similar improvement in diastolic left ventricular (LV)
function at 4 months. There is another unanswered question
concerning the effect of BMC therapy on exercise capacity.
Symptoms of cardiac disease generally manifest during
exercise, and it is well known that resting parameters of LV
systolic function correlate poorly with exercise capacity
(Franciosa et al., 1981). Changes in exercise capacity may
be the result of changes in cardiac diastolic function. The
BALANCE (Yousef et al., 2009) and ASTAMI (Beitnes et al.,
2009) studies could not come to a consistent conclusion
regarding the effect of stem cells on exercise capacity. Among
research methodologies, meta-analysis is most useful when
there is no adequately powered, prospective, randomized
study to answer the question at hand. This meta-analysis
attempted to determine whether autologous BMCs are bene-
ficial to LV diastolic function and exercise capacity after AMI.
Results
Search results
The initial search identified 642 articles (Fig. 1), of which 572
were on gene-mediated stem cell therapy, thrombolytic
therapy after MI, granulocyte colony-stimulating factor (G-Figure 1 Review process.This scheme provides a summary of
the systematic review process.CSF)-stimulated therapy, non-randomized controlled trials
(RCTs), animal experiments, editorials or reviews. Of the
remaining 70 RCTs examined in more detail, 9 articles were
either on-going trials, lacked a non-cell control group, BMC
treatment for chronic MI, or percutaneous coronary interven-
tion (PCI) that was performed against current guidelines
(Miettinen et al., 2010). Fifty-two articles were excluded for
having endpoints unrelated to diastolic function and exercise
capacity. Nine articles involving a total of 365 patients were
eligible for review (Beitnes et al., 2011, 2009; Herbots et al.,
2009; Lunde et al., 2007; Piepoli et al., 2010; Plewka et al.,
2009; Schaefer et al., 2006, 2010; Straburzynska-Migaj et al.,
2011). The inter-reviewer agreement on study eligibility was
100%.Study characteristics
Table 1 describes the methodological quality of the RCTs.
Table 2 summarizes the main features of the included trials.
The sample sizes were 38–100 patients, and the follow-up
duration was 3–60 months. All of the trials contained patients
who presented with a ST-segment elevation AMI. Standard
echocardiography and tissue Doppler echocardiography were
used to acquire diastolic parameters. All of the patients
received optimal medical treatment, including aspirin, clopi-
dogrel, an angiotensin converting enzyme inhibitor or angio-
tensin II receptor blocker, β-blocker and statin. Table 3
presents the characteristics of all of the trials included in our
systematic analysis. The overall baseline characteristics were
well matched. All of the trials with BMCs used intracoronary
injection. The cell dose and time from PCI to cell therapy are
shown in detail (Table 3).Mean difference in cardiac diastolic parameters
We grouped the studies based on the length of the follow-up
period. The pooled data showed that BMC therapy was
superior to standard medical therapy for improving inflow E
velocity to tissue Doppler Ea ratio (E/Ea ratio) after 1 year of
follow-up (1.01, 95% CI 0.93 to 1.08; pb0.00001; I2=0%)
(Fig. 2A). A reduced Ea was observed in stem cell-treated
patients during the same follow-up period. Ea decreased by
0.34 cm/s in the BMC group compared to the control group
(95% CI −0.64 to −0.05; p=0.02; I2=94.1%) (Fig. 2B). This
result does not cancel out the overall benefit to cardiac
function, as reflected by the improved E/Ea ratio in the BMC
group, which is possibly attributed to the lowering of the
cardiac filling pressures, left atrial pressure and, consequent-
ly, a larger reduction in the early mitral flow velocity. For
pulmonary vascular resistance (PVR), we found a benefit in the
BMC group within 1 year. The PVR was lower (−0.01, 95% CI
−0.02 to 0.00; p=0.004; I2=81.2%) in the BMC group compared
to the control group (Fig. 2C). Due to limited data, it was
impossible to analyze the group differences for PVR after the
1-year follow up. Other conventional diastolic function vari-
ables, including transmitral early peak (E)/late peak (A)
velocities (E/A ratio), E-wave deceleration time (DT), and
isovolumic relaxation time (IVRT), did not show differences
between the BMC and control groups (data not shown).
Table 1 Quality assessment scale for the RCTs included in the systematic analysis.
Selection Performance Detection Attrition
Source of bias Was the
allocation
adequate?
Was an adequate
method of
randomization
described?
Were the groups
similar at the start
of the study?
Were the patients/care
givers blinded to the
intervention?
Was the
outcome
ascertained
blindly?
What percentage
was lost to follow
up? (%)
Were all patients analyzed in the
group that they were assigned
(intention-to-treat analysis)?
Herbots et al. (2009) A A A A A 1.5 Yes
BOOST (Schaefer et al., 2006, 2010) A A A A A 5.1 No
ASTAMI (Beitnes et al., 2011, 2009;
Lunde, et al., 2007)
A A A C C 3 Yes
Plewka et al. (2009) A B A A B 0 Yes
CARDIAC STUDY (Piepoli et al., 2010) A A A B A 0 Yes
Ewa et al.(Straburzynska-Migaj
et al., 2011)
A A A C B 0 Yes
A: adequate; B: unclear or not reported in the published data; C: inadequate. “Adequate” means the use of a central site, numeric code, opaque envelopes, drugs prepared by pharmacy, and
other appropriate procedures. Adapted from Juni et al. (2001).
Table 2 Characteristics of the trials included in the systematic analysis.
Source Sample size Mean follow up (mo) Study design Setting Sham infusion Clinical scenario OPT
Herbots et al. (2009) 67 4 RCT Single center Yes AMI Yes
BOOST (Schaefer et al., 2006, 2010) 59 6, 18, 60 RCT Single center Yes AMI Yes
ASTAMI (Beitnes et al., 2011, 2009; Lunde et al., 2007) 100 6, 36 RCT Two centers No AMI Yes
Plewka et al. (2009) 56 6 RCT Single center No AMI Yes
CARDIAC STUDY (Piepoli et al., 2010) 38 3, 6, 12 RCT Single center NR AMI Yes
Ewa et al.(Straburzynska-Migaj et al., 2011) 45 3, 6, 12 RCT Single center NR AMI Yes
Mo: month; NR: not reported; AMI: acute myocardial infarction; OPT: optimal pharmaceutical treatment.
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Table 3 Patients and procedural characteristics of the included trials.
Study Mean Age
(years)
Men
(%)
Hours
to PCI
Time from PCI
to cell therapy
Mean cell
dose (106)
Delivery
method
Herbots et al. (2009) 57 84 3.7 4–6 hours 172 (BMC)
2.8 (CD34+)
IC
BOOST (Schaefer et al., 2006, 2010) 56 69 9.8 4.5 days 2460 (BMC)
9.5 (CD34+)
IC
ASTAMI (Beitnes et al., 2011, 2009; Lunde, et al., 2007) 57 84 4.4 6 days 68 (BMC)
0.7 (CD34+)
IC
Plewka et al. (2009) 56 71 7 7 days 144 (BMC)
3.1 (CD34+)
IC
CARDIAC STUDY (Piepoli et al., 2010) 65 68 4.1 4 days 418 (BMC)
2 (CD34+)
IC
Ewa et al.(Straburzynska-Migaj et al., 2011) 50 64 b12 4–6 days 410 (BMC)
3.9 (CD34+)
IC
IC: intracoronary cell therapy; PCI: percutaneous coronary intervention.
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Despite the statistical significance of the benefit of intracor-
onary BMC delivery after AMI on cardiac diastolic function,
meaningful clinical benefits need to be explored further.
Table 4 is a summary of the magnitude of the changes after
cell therapy (in absolute units or as percentages) and gives a
true reflection of the potential benefit. The E/Ea ratio was
worse in the control group compared to the BMC-treated group
(absolute value: 12.3 vs. 11.8) after 1 year of follow up. The
PVR decreased by a further 4.88% in the BMC-treated group
compared to the placebo group. The result for Ea may not be
clinically significant because the magnitude of the effect
appeared to be minimal, and it is highly improbable that this
effect was associated with any meaningful clinical benefit.
Sensitivity analysis and publication bias
A sensitivity analysis, excluding each individual study,
confirmed the statistical significance of the results from the
overall analysis (data not shown). BMC therapy was superior to
standard medical therapy. No publication bias was found.
Mean difference in exercise capacity
Regarding exercise capacity, there was a greater increase in
exercise time [0.69, 95% CI 0.30 to 1.09; p=0.0005; I2=89.0%]
(Fig. 3A), a further decrease in the peak oxygen consumption
ventilation/CO2 production (VE/VCO2 slope) [−1.18, 95% CI
−2.24 to −0.12; p=0.03; I2=95.2%] (Fig. 3B) and a slight
improvement in the respiratory exchange ratio (RER) [−0.01,
95% CI −0.02 to 0.00; p=0.01; I2=18.8%] (Fig. 3C) in the BMC
group compared to the control group at 1 year and beyond. No
significant treatment-related differences in peak VO2 change
were noted between the two groups [0.74, 95% CI −2.79 to
4.27; p=0.68; I2=99.2%] (figure not shown).
Consistent with the above findings, patients treated with
BMC experienced a 14.29-minute improvement in exercise
time after 1 year of follow up compared to a 4.76-minute
increase in the placebo group. Additionally, there was a
clinically significant decrease in the VE/VCO2 slope in the BMC
group.Discussion
The findings from the trials are listed as follows: 1) BMC
therapy after AMI has been shown to lead to a mild mid-term
improvement in diastolic cardiac function, including E/Ea
and PVR, compared to the control group; 2) this improve-
ment was accompanied by an improved exercise capacity
after 1 year of follow up.
The E/A ratio, DT and IVRT have a biphasic relationship to
LV diastolic properties and filling pressure. Patients with AMI
may have pseudo-normal or restrictive mitral flow patterns
at baseline due to a high filling pressure. Changes in these
parameters should therefore be interpreted with caution.
Modern tissue Doppler measurements of LV diastolic function
may be more sensitive than traditional echocardiographic
methods for risk prediction. E/Ea is a non-invasive, repro-
ducible index, even beyond the usual Doppler parameters.
E/Ea has been extensively correlated with invasively
measured LV diastolic pressures regardless of LV ejection
fraction (Bruch et al., 2005). E/Ea is the strongest predictor
of primary cardiac events and represents a simple, effective
tool for assessing cardiac risk in a hypertensive population
(Sharp et al., 2010) and for assessing heart failure (HF)
(Bruch et al., 2007). Therefore, we chose E/Ea as our
primary endpoint. Because all diastolic indices have limita-
tions, a comprehensive evaluation was conducted. A further
decrease in E/Ea and other tissue Doppler indicators was
observed in the BMC group, which probably reflects a
decrease in the LV filling pressure during recovery after
AMI. Combined with other indices, a decreased PVR
corresponded to a decrease in left atrial pressure and LV
filling pressures after BMC therapy. These findings suggest
that the BMC transfer group recovered from a very mild form
of early diastolic dysfunction and may have improved
survival after AMI.
One may argue that at the long-term follow up (3–5 years)
for diastolic function, patients in the BMC group did not
achieve further benefits compared to the control group. It is
well known that diastolic function is related to myocardial
relaxation and passive LV properties. After myocardial
infarction, improved systolic function was observed in BMC-
treated patients (Plewka et al., 2009). Enhanced systolic
function could result in increased restorative forces, which
Figure 2 Impact of BMCs on diastolic function.Forest plots showed the significantly beneficial impact of BMC therapy after acute
myocardial infarction on (a) E/Ea, (b) Ea, and (c) PVR. BMC=bone marrow-derived cells; E=transmitral peak early (E) velocities;
Ea=septal and lateral sides of the mitral annulus early diastolic velocities; PVR=pulmonary vascular resistance; WMD=weighted
mean difference; CI=confidence interval; I2= inconsistency; SD=standard deviation.
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PVR, and lead to an improvement in early diastolic relaxation
and passive myocardial movement. Because systolic function
only exhibited mild to moderate improvement in the first few
months, it is possible that BMC therapy was not responsible for
the long-term beneficial effect on diastolic function. Wemust
be cautious about the current long-term results of BMC
transplantation regarding diastolic function because only two
trials, with a total of 156 patients, were available at this stage
(Beitnes et al., 2011; Schaefer et al., 2010). Furthermore, the
long-term results may be influenced by many other un-
certainties; years after the cell therapy, any impact of BMCs
could become minimal.Diastolic function was influenced by the following events
after MI: cell necrosis, residual ischemia, microvascular
dysfunction, and regional wall motion abnormalities. We
propose that the short-term improvement in diastolic function
was due to restoration of microvascular function. BMC trans-
plantation has been found to improve myocardial perfusion in
patients with AMI (Grajek et al., 2010) and chronic MI (Yao et
al., 2008). Diastolic function was also improved. In the
recently published Doppler substudy of the REPAIR-AMI trial
(Erbs et al., 2007), Erbs et al. found that intracoronary
infusion of BMCs in AMI patients after reperfusion was
associated with a normalization of coronary flow reserve in
the infarct-related artery within 4 months and a profound
Table 4 Magnitude of the changes after therapy.
Cardiac variables Parameters Follow up (year) Treatment Group Mean Control Group Mean
Diastolic Function E/Ea ≥1 11.8 12.3
PVR % b1 −6.19 −1.31
Ea (cm/s) ≥1 6.70 6.94
Exercise Capacity exercise time (min) ≥1 14.29 4.76
VE/VCO2 slope (%) ≥1 −2.18 1.20
E/Ea: mitral inflow E velocity to tissue Doppler Ea ratio; PVR: pulmonary vascular resistance; VE/VCO2 slope: oxygen consumption (VO2)
and ventilation/CO2 production.
Figure 3 Impact of BMCs on exercise capacity.Forest plots showed the significantly beneficial impact of BMC therapy after acute
myocardial infarction on exercise time (a) VE/VCO2 and (b) RER (c) after a 1-year follow up. BMC=bone marrow-derived cells;
VE/VCO2 slope=ventilation/CO2 production; RER=respiratory exchange ratio; WMD=weighted mean difference; CI=confidence
interval; I2= inconsistency; SD=standard deviation.
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Second, the reduced LV collagen density may also partially
account for the improvement in diastolic function (Zhang et
al., 2004).
We subsequently examined the effect of BMC therapy on
exercise capacity. We found that exercise time and the VE/
VCO2 slope improved in the BMC group. VE/VCO2 is the
strongest predictor of cardiac-related events after 1 year. In
HF, the VE/VCO2 slope is steeper and is a marker for poor
prognosis. The improvement in exercise time and the RER
may indicate increased exercise duration and intensity,
which also indicates a better prognosis. Whereas exercise
capacity correlates poorly with resting LVEF (Franciosa et
al., 1981), improved diastolic LV function after BMC therapy
improves cardiac performance during stress (Schaefer et al.,
2006). In addition, abnormal values for E/Ea are indepen-
dently associated with reduced exercise performance,
regardless of LV systolic and diastolic function (Arques et
al., 2007). The observed improvement in exercise capacity
was consistent with the change in E/Ea; thus, improved
exercise capacity could partly be a result of the change in E/
Ea.
Limitations: In this review, we propose a preliminary
conclusion while being aware of the unavoidable limitations
of our meta-analysis. 1) Some of the trials were small, and
all of the data did not come from double-blind trials. 2)
Echocardiography is known for its inter-observer variation
and being prone to bias. 3) The statistical heterogeneity
relates to the nature of randomization (double blind or
open-label) and the infused BMC dose. 4) Additionally, with
a slight to moderate change in exercise time, VE/VCO2 and
RER, they may not be enough to measure a change in overall
exercise capacity.Conclusion
Adult BMC therapy for AMI appeared to provide mid-term
benefits for diastolic function and exercise capacity. BMCs
may be a feasible adjuvant to current AMI therapy.Materials and methods
Review question and study protocol
We attempted to answer the following question: Based on
the current RCTs, does autologous BMC infusion improve LV
diastolic function and exercise capacity after AMI? We
reported this protocol-driven, systematic review according
to the quality of meta-analysis reporting (PRISMA) (Moher et
al., 2009) statements.Eligibility criteria
The reviewers independently judged the eligibility for study
inclusion in the analysis. Eligible studies were RCTs that
examined the effects of adult progenitor cell transplantation
on acute myocardial function and structure in patients after
AMI. Because cytokines may exert cardiovascular effects and
mobilize endogenous progenitor cells, we excluded studiesthat administered cytokines, such as granulocyte colony-
stimulating factor (G-CSF).
Search strategy
We searched the MEDLINE, EMBASE, Science Citation Index
and the Cochrane Central Register of Controlled Trials
databases through Aug 1, 2011, and the American College of
Cardiology, American Heart Association, European Society of
Cardiology and Transcatheter Cardiovascular Therapeutics
conference proceedings from the years 2000 to 2011. We also
searched internet-based sources of information on clinical
trials in cardiology for RCTs using the following keywords:
coronary artery disease, acute myocardial infarction, stem
cells, progenitor cells, bone marrow, circulating progenitor
cells, diastolic function, exercise capacity and cardiac repair.
Initially, the selected citations were screened at the title/
abstract level and, if potentially relevant, retrieved and
assessed as complete manuscripts for compliance with the
following inclusion criteria: 1) prospective comparison of stem
cell therapy vs. placebo control after AMI in which the infarct-
related artery was treated by percutaneous coronary inter-
vention (PCI) or coronary artery bypass grafting (CABG); 2)
follow-up of ≥3 months; 3) PCI or CABG in combination with
standard medical treatment was regarded as the control. The
exclusion criteria were the following: 1) unclear data or
ongoing or unpublished studies; 2) a lack of a control group or
the use of other cells as a control group; 3) BMC therapy for
chronic myocardial infarction; 4) PCI that was performed
against current guidelines; 5) the administration of cytokines,
such as G-CSF; 6) non-randomized, non-controlled, or cross-
over studies. Therewas no restriction based on the publication
year or language.
Data extraction and quality assessment
The reviewers worked independently of each other and used a
standardized form to extract the data from each study. The
corresponding author reassessed the trials when a disagree-
ment was encountered. We used the criteria established by
Juni et al. (2001) to ascertain the methodological quality of
the included RCTs.
Data analysis
Endpoint and data extraction
Several study features were extracted, including design,
outcome definitions, patient baseline characteristics, and
procedural data. Inter-group analyses of diastolic LV param-
eters were based on the change from baseline data for the cell
and control groups by echocardiography or tissue Doppler. The
diastolic function parameters included change in E/A, DT, and
IVRT from baseline to follow up. PVR was determined as the
mean pulmonary artery pressure/pulmonary blood flow×80.
Tissue Doppler signals were acquired at least at the septal and
lateral sides of the mitral annulus and were presented as the
average values. The indices included changes in mitral inflow
E/Ea ratio. We made E/Ea the primary endpoint because E/Ea
is a noninvasive parameter for estimating LV diastolic function
and is the strongest predictor of primary cardiac events
(Arques, 2009; Groban et al., 2010). Exercise capacity
56 M. Jiang et al.measurements included exercise time (minutes), VO2, VE/
VCO2 slope, and RER. All of the outcomes analyzed were
defined in the individual trials. In case of missing or unclear
data for the primary or secondary endpoints, at least 2
separate attempts at least 3 weeks apart were made to clarify
the data by contacting the primary authors.
Statistical analysis
We conducted random-effects meta-analyses to pool these
outcomes from the included studies and estimate the
weighted mean differences (WMD) between the adult
progenitor cell-treated patients and control patients and
their associated 95% confidence intervals (CIs). We estimat-
ed the proportion of inter-study inconsistency due to true
differences between the studies using the I2 statistic
(Higgins et al., 2003). We used Rev-Man version 4.2.2 for
these analyses. To give readers an accurate picture of the
potential clinical benefit, we also presented the magnitude
of the changes during the follow-up on variables in each
group using funnel plots that indicated significant differ-
ences. Sensitivity analyses were conducted to evaluate the
robustness of our results. We removed each study individu-
ally to evaluate that study's effect on the summary
estimates. Finally, publication bias was appraised by visual
inspecting the funnel plots and using the Egger test.
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